Patent · US Active

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

US8507663B2 · kind B2 · utility

13Cited by

0References

16Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Antonin DeFougerolles · Cambridge, US
Tatiana Novobrantseva · Cambridge, US
Brian Bettencourt · Groton, US

Key dates

Filing date	Apr 6, 2011
Grant date	Aug 13, 2013
Priority date	—
Expiry date	Apr 6, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.